Risk factors of BK viral hemorrhagic cystitis in allogenic hematopoietic stem cell transplantation.


Journal

Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688

Informations de publication

Date de publication:
Oct 2021
Historique:
revised: 01 02 2021
received: 06 10 2020
accepted: 08 02 2021
pubmed: 17 3 2021
medline: 3 11 2021
entrez: 16 3 2021
Statut: ppublish

Résumé

Reactivation of BK virus (BKV) can occur during intensive immunosuppression such as in allogenic hematopoietic stem cell transplant (AHSCT) recipients for whom a systematic PCR urine test for BKV will be positive in 50% to 100% of patients. Only 5% to 40% will develop BKV hemorrhagic cystitis (HC). Thus, BKV PCR testing is useful to confirm a diagnosis of BKV-HC but not to predict its occurrence. The aim of this retrospective study was to ascertain the risk factors of developing BKV HC, mostly in patients receiving posttransplant cyclophosphamide. The study looked at data from Grenoble Alpes University Hospital included in the national retrospective register ProMISe, administered by the "Société Francophone de Greffe de Moelle et de Thérapie Cellulaire". Urine BKV PCR was performed when patients presented grade ≥ 2 hematuria with clinical symptoms of cystitis. BKV-HC was defined as an association of clinical symptoms of cystitis, grade ≥ 2 hematuria and BKV viruria > 7 log

Identifiants

pubmed: 33724650
doi: 10.1111/tid.13601
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13601

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Reploeg MD, Storch GA, Clifford DB. Bk virus: a clinical review. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;33(2):191-202.
van Aalderen MC, Heutinck KM, Huisman C, ten Berge IJM. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. Neth J Med. 2012;70(4):172-183.
de Silva LP, Patah PA, Saliba RM, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica. 2010;95(7):1183-1190.
Gilis L, Morisset S, Billaud G, et al. High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2014;49(5):664-670.
Erard V, Storer B, Corey L, et al. BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;39(12):1861-1865.
Giraud G, Bogdanovic G, Priftakis P, et al. The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica. 2006;91(3):401-404.
Uhm J, Hamad N, Michelis FV, et al. The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD. Bone Marrow Transplant. 2014;49(12):1528-1534.
Bogdanovic G, Priftakis P, Giraud G, et al. Association between a high BK virus load in urine samples of patients with graft-versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation. J Clin Microbiol. 2004;42(11):5394-5396.
Giraud G, Priftakis P, Bogdanovic G, et al. BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplant. 2008;41(8):737-742.
Lunde LE, Dasaraju S, Cao Q, et al. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. Bone Marrow Transplant. 2015;50(11):1432-1437.
Rimondo A, Crocchiolo R, El-Cheikh J, et al. The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2017;52(1):135-137.
Ruggeri A, Roth-Guepin G, Battipaglia G, et al. Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. Transpl Infect Dis Off J Transplant Soc. 2015;17(6):822-830.
Bedi A, Miller CB, Hanson JL, et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol Off J Am Soc Clin Oncol. 1995;13(5):1103-1109.
Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2012;18(12):1859-1866.
Cesaro S, Dalianis T, Hanssen Rinaldo C, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018;73(1):12-21.
Arango M. Hemorrhagic cystitis after haploidentical transplantation with post-transplant cyclophosphamide: protective effect of MESNA continuous infusion: Lower incidence of hemorrhagic cystitis after haplo-HSCT with MESNA continuous infusion. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2020:1492-1496.
El-Zimaity M, Saliba R, Chan K, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood. 2004;103(12):4674-4680.
Umeda K, Kato I, Kawaguchi K, et al. High incidence of BK virus-associated hemorrhagic cystitis in children after second or third allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2018;14:e13183.
Cesaro S, Facchin C, Tridello G, et al. A prospective study of BK-virus-associated haemorrhagic cystitis in paediatric patients undergoing allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:363-370.
Bogdanovic G, Priftakis P, Giraud G, Dalianis T. A related donor and reduced intensity conditioning reduces the risk of development of BK virus-positive haemorrhagic cystitis in allogeneic haematopoetic stem cell-transplanted patients. Anticancer Res. 2006;26:1311-1318.
Nakamae H, Fujii K, Nanno S, et al. A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from. Transpl Int Off J Eur Soc Organ Transplant. 2019;32(12):1322-1332.
Desjonqueres A, Illiaquer M, Duquesne A, et al. Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation. Bone Marrow Transplant. 2016;51(8):1150-1152.
O'Donnell PH, Swanson K, Josephson MA, et al. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2009;15(9):1038-1048.e1.
Laskin BL, Denburg MR, Furth SL, et al. The natural history of BK polyomavirus and the host immune response after stem cell transplantation. Clin Infect Dis. 2019;71(12):3044-3054.
Imlay H, Xie HU, Leisenring WM, et al. Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Blood Adv. 2020;4(4):617-628.

Auteurs

Eléonore Kaphan (E)

Department of Hematology, Bone Marrow Transplant Unit, CHU Grenoble Alpes, Grenoble, France.

Raphaele Germi (R)

Laboratory of Virology, Grenoble University Hospital, Grenoble, France.

Sébastien Bailly (S)

Institut de Biologie Structurale, UMR5075 CEA-CNRS-UGA, Grenoble, France.
University of Grenoble Alpes, Inserm, CHU Grenoble Alpes, Grenoble, France.

Claude-Eric Bulabois (CE)

Department of Hematology, Bone Marrow Transplant Unit, CHU Grenoble Alpes, Grenoble, France.

Martin Carré (M)

Department of Hematology, Bone Marrow Transplant Unit, CHU Grenoble Alpes, Grenoble, France.

Jean-Yves Cahn (JY)

Department of Hematology, Bone Marrow Transplant Unit, CHU Grenoble Alpes, Grenoble, France.

Anne Thiebaut-Bertrand (A)

Department of Hematology, Bone Marrow Transplant Unit, CHU Grenoble Alpes, Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH